PCDH12

Across TCGA pan-cancer cohorts, PCDH12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCDH12 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCDH12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PCDH12 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where PCDH12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.275	0.610	.002	39	view →
LUAD	DFS	Tertile	II,III,IV	0.745	0.971	<.001	26	view →
HNSC	OS	Median	III,IV	0.930	0.574	.017	8	view →
LSCC	DFS	Tertile	II,III,IV	0.800	1.000	.007	5	view →
GBM	OS	Quartile	All	0.233	0.493	.012	4	view →
CCRCC	DFS	Median	III,IV	1.000	0.761	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCDH12–PDAC (OS)

Open the PDAC breakdown →